Target Trial Emulation brings the logic of randomized trials into real-world data
Target Trial Emulation does not replace randomized controlled trials, but it applies their logic and rigor to real-world data analysis.
Hospital data lakes offer clinicians diverse real-world data (RWD) that supports their work. Dr. Heikki Ekroos, Chief Physician of Pulmonary Diseases at Helsinki University Hospital (HUS) Porvoo Hospital, presented real-world evidence (RWE) studies that were based on HUS data lakes data at Medaffcon’s EMMA client event.
The Helsinki University Hospital (HUS) data lake contains a vast amount of healthcare data on the population in the Helsinki-Uusimaa Region. This data lake includes healthcare data of 3.5 million individuals and, among other things, 37 million patient records and 790 million laboratory results.
Dr. Heikki Ekroos, Chief Physician of Pulmonary Diseases at Helsinki University Hospital (HUS) Porvoo Hospital, is involved in studies that investigate the relationship between smoking and surgical complications and their associated costs. Other ongoing studies explore the profiles of sleep apnea patients and treatment outcomes for lung cancer patients.
The lung cancer study includes all data from patients diagnosed between 2013 and 2023. The data is extracted from the Helsinki University Hospital (HUS) data lake. This study includes all available information, such as healthcare visits, treatments, genetics, pathology, and laboratory tests.
The results provide information, among other things, on treatment outcomes and will help clinicians make evidence-based treatment decisions.
-Previously, we didn’t have any data on lung cancer treatment outcomes. Yet, we are constantly taking actions and administering expensive medications. It’s essential to know what happens to patients. Now we get real-world data (RWD) quite rapidly, says Dr. Heikki Ekroos, Chief Physician of Pulmonary Diseases at Helsinki University Hospital (HUS) Porvoo Hospital.
A registry study on the relationship between smoking and surgical complications was published in March 2023. Its data consisted of all surgeries performed in the Helsinki University Hospital (HUS) area between 2015 and 2019.
The study showed that current and former smokers have a significantly increased risk of experiencing complications after surgery. This study was also a great example of the possibilities that machine learning and hospital data lakes provide for research.
– It was important for me that we obtained scientific results on the effects of smoking on surgical recovery. Now we have a strong argument for why it’s worth quitting smoking before surgery, says Dr. Heikki Ekroos, Chief Physician of Pulmonary Diseases at HUS Porvoo Hospital, who led the study.
The dataset for the study covered about a million surgeries. Initially, clinicians reviewed 20,000 patient records and classified patients as smokers, quitters, or non-smokers. This classification was used to teach a machine learning algorithm.
By using machine learning and artificial intelligence, smoking data for over a million surgeries was determined. The algorithm distinguished smokers, quitters, and non-smokers from patient records. Physicians had predefined the complications being sought. Ultimately, 158,638 surgeries were left for AI analysis.
According to Ekroos, Medaffcon’s expertise was essential for the project and helped define how to use the data.
-At the beginning of the project, it is necessary to define what data is being sought. Medaffcon also helped integrate machine learning into the study. Without machine learning, handling such a large amount of data would have been impossible, Dr. Heikki Ekroos, Chief Physician of Pulmonary Diseases at Helsinki University Hospital (HUS) Porvoo Hospital explains.
Medaffcon’s EMMA event was held on April 10, 2024. Dr. Heikki Ekroos, Chief Physician of Pulmonary Diseases at HUS Porvoo Hospital, spoke at the event about real-world research from a clinician’s perspective.
Medaffcon, founded in 2009, is a Nordic research and consulting company specializing in Real-World Evidence, Medical Affairs, and Market Access. With offices in Stockholm, Sweden, and Espoo, Finland, we provide expert services across the Nordic region. Our services combine strong medical and health economic expertise with modern data science.
The company employs some 30 experts. Since 2017, Medaffcon has been a subsidiary of Tamro Oyj and is part of the PHOENIX group, which is a leading provider of healthcare services in Europe.
Target Trial Emulation does not replace randomized controlled trials, but it applies their logic and rigor to real-world data analysis.
The data team keeps Medaffcon's research projects on track and ensures that the research findings are scientifically sound. At the heart of the team’s work is the processing and analysis of patient data, particularly in Real-World Evidence (RWE) studies.
Medaffcon's European Lung Cancer Congress (ELCC) poster showcased key findings from a recent study on non-small cell lung cancer (NSCLC).
Sr. Scientific Advisor
RWE Lead
PhD
+358 50 345 2393
mariann.lassenius@medaffcon.com
Mariann joined Medaffcon’s team in 2016 after finishing her PhD. The transition to real world evidence (RWE) research was a natural continuum to her previous research career. Through RWE studies, she has had the privilege to gain a broad insight into working with different stakeholders within the healthcare field. The vast proportion of her days goes towards interacting with clients, planning and performing RWE studies, and supporting Medaffcon’s RWE team. Subjects that keep her work interesting are the vast variability of customers and projects, problem-solving, and interacting with people.
“The number of RWE studies has increased since stakeholders within the healthcare industry have an increasing demand for knowledge-based decision making tools that need to be fulfilled. The future, therefore, has an ever-increasing emphasis on RWE”.